[go: up one dir, main page]

SV2003001076A - COMPOUNDS AND ANTITUMOR PROCEDURES REF. X-14776 - Google Patents

COMPOUNDS AND ANTITUMOR PROCEDURES REF. X-14776

Info

Publication number
SV2003001076A
SV2003001076A SV2002001076A SV2002001076A SV2003001076A SV 2003001076 A SV2003001076 A SV 2003001076A SV 2002001076 A SV2002001076 A SV 2002001076A SV 2002001076 A SV2002001076 A SV 2002001076A SV 2003001076 A SV2003001076 A SV 2003001076A
Authority
SV
El Salvador
Prior art keywords
procedures
compounds
antitumor
ref
antitumoral
Prior art date
Application number
SV2002001076A
Other languages
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SV2003001076A publication Critical patent/SV2003001076A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

COMPUESTOS ANTITUMORALES DE FORMULA (VER FORMULA) Y PROCEDIMIENTOS ANTITUMORALES.FORMULA ANTITUMORAL COMPOUNDS (SEE FORMULA) AND ANTITUMORAL PROCEDURES.

SV2002001076A 2001-06-06 2002-06-05 COMPOUNDS AND ANTITUMOR PROCEDURES REF. X-14776 SV2003001076A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29635001P 2001-06-06 2001-06-06

Publications (1)

Publication Number Publication Date
SV2003001076A true SV2003001076A (en) 2003-07-29

Family

ID=23141662

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2002001076A SV2003001076A (en) 2001-06-06 2002-06-05 COMPOUNDS AND ANTITUMOR PROCEDURES REF. X-14776

Country Status (35)

Country Link
US (1) US7183320B2 (en)
EP (1) EP1401806B1 (en)
JP (1) JP4167173B2 (en)
KR (1) KR100880760B1 (en)
CN (1) CN100475787C (en)
AR (1) AR036079A1 (en)
AT (1) ATE335722T1 (en)
AU (1) AU2002259204B2 (en)
BR (1) BR0210078A (en)
CA (1) CA2446719A1 (en)
CR (1) CR7182A (en)
CY (1) CY1105386T1 (en)
CZ (1) CZ20033296A3 (en)
DE (1) DE60213810T2 (en)
DK (1) DK1401806T3 (en)
EA (1) EA005810B1 (en)
EC (1) ECSP034874A (en)
EG (1) EG24356A (en)
ES (1) ES2269688T3 (en)
HR (1) HRP20031000A2 (en)
HU (1) HUP0400114A3 (en)
IL (1) IL158985A0 (en)
MX (1) MXPA03011197A (en)
MY (1) MY136855A (en)
NO (1) NO20035366L (en)
NZ (1) NZ529098A (en)
PE (1) PE20030199A1 (en)
PL (1) PL367188A1 (en)
PT (1) PT1401806E (en)
SK (1) SK14642003A3 (en)
SV (1) SV2003001076A (en)
TW (1) TWI266761B (en)
UA (1) UA74889C2 (en)
WO (1) WO2002098848A1 (en)
ZA (1) ZA200308644B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375978T1 (en) 2002-11-22 2007-11-15 Lilly Co Eli BENZOYLSULFONAMIDE AS AN ANTITUMOR AGENT
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
JP5284641B2 (en) * 2004-05-26 2013-09-11 アボット・ラボラトリーズ N-sulfonylcarboximidamide apoptosis promoter
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
JP5134247B2 (en) * 2004-09-13 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 Combination of sulfonamide-containing compounds with angiogenesis inhibitors
SI1859793T1 (en) * 2005-02-28 2011-08-31 Eisai R&D Man Co Ltd Novel combinational use of a sulfonamide compound in the treatment of cancer
WO2006090921A1 (en) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Inhibitory effect of sulfonamide compound on lymphocyte activation
AU2006217690B2 (en) * 2005-02-28 2012-03-15 Eisai R & D Management Co., Ltd. Novel use of sulfonamide compound in combination with angiogenesis inhibitor
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
NZ561609A (en) 2005-05-12 2010-03-26 Abbott Lab 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters
US7208526B2 (en) 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
US7208506B2 (en) * 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US7625896B2 (en) * 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
JPWO2007123274A1 (en) 2006-04-20 2009-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 Novel sensitivity markers for sulfonamide compounds
CA2662320C (en) 2006-09-05 2014-07-22 Abbott Laboratories Bcl inhibitors treating platelet excess
US7939532B2 (en) 2006-10-26 2011-05-10 Hoffmann-La Roche Inc. Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
JP2010526844A (en) * 2007-05-16 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー Arylpyridylsulfonamide derivatives, their preparation and use as pharmaceutical agents
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
PT2511264E (en) * 2009-01-19 2015-07-17 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2012136435A (en) * 2009-03-30 2012-07-19 Eisai R & D Management Co Ltd Method for examining sensitivity of tumor tissue
KR200457823Y1 (en) * 2009-05-08 2012-01-05 황정용 Zucchini catching gear
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2944638A1 (en) 2009-05-26 2015-11-18 AbbVie Bahamas Limited Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
ES2553143T3 (en) * 2010-03-25 2015-12-04 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
UA113500C2 (en) 2010-10-29 2017-02-10 MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
JP6068352B2 (en) 2010-10-29 2017-01-25 アッヴィ・インコーポレイテッド Solid dispersion containing apoptosis inducer
CA2817629C (en) 2010-11-23 2019-08-13 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
ES2603129T3 (en) 2010-11-23 2017-02-23 Abbvie Ireland Unlimited Company Treatment methods using selective Bcl-2 inhibitors
CN103159650B (en) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 The preparation of aromatic heterocycle sulfamide compound and application thereof
CN103159649B (en) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 The preparation of sulfamide compound and application thereof
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN105712925B (en) * 2014-12-05 2019-01-04 沈阳中化农药化工研发有限公司 A kind of substituted sulfoamido (thio) carbonyls and application thereof
MA41542A (en) 2015-02-13 2021-04-14 Oxford Drug Design Ltd NEW N-ACYL-ARYLSULFONAMIDE DERIVATIVES USED AS AMINOACYL-ARNT SYNTHETASE INHIBITORS
CN105753748B (en) * 2016-02-15 2018-05-29 南京励合化学新材料有限公司 A kind of synthetic method of medicine intermediate sulphonyl class compound
GB201617064D0 (en) 2016-10-07 2016-11-23 Inhibox Limited And Latvian Institute Of Organic Synthesis The Compounds and their therapeutic use
WO2018192462A1 (en) 2017-04-18 2018-10-25 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
US11479532B2 (en) * 2017-06-23 2022-10-25 University Of South Florida 5-aminolevulinate synthase inhibitors and methods of use thereof
WO2019133797A1 (en) * 2017-12-29 2019-07-04 Wu, Lester J. Benzenesulfonamide derivatives and method for modulating lipid raft
CN114790149B (en) * 2021-01-26 2024-11-19 江苏中旗科技股份有限公司 A method for synthesizing 2-chloro-4-fluorobenzoic acid using 2-chloro-4-fluoroaniline as raw material
CN119462555A (en) * 2023-08-09 2025-02-18 上海科技大学 Sulfonamide compounds and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4157257A (en) 1976-10-01 1979-06-05 Utsunomiya University Benzenesulfonamide derivatives
US4347380A (en) * 1979-04-20 1982-08-31 Stauffer Chemical Company N-Acylsulfonamide herbicidal antidotes
US4266078A (en) * 1979-04-20 1981-05-05 Stauffer Chemical Company N-Acylsulfonamide herbicidal antidotes
US4433997A (en) * 1979-04-20 1984-02-28 Stauffer Chemical Co N-Acylsulfonamide herbicidal antidotes
US4495365A (en) * 1980-11-21 1985-01-22 Stauffer Chemical Co. N-Acylsulfonamide herbicidal antidotes
US4845128A (en) * 1984-06-27 1989-07-04 Eli Lilly And Company N([(4-trifluoromethylphenyl)amino]carbonyl)benzene sulfonamides
US5110830A (en) * 1984-06-27 1992-05-05 Eli Lilly And Company Benzenesulfonamides treatment of tumors susceptible to
JP2679498B2 (en) * 1991-12-25 1997-11-19 王子製紙株式会社 Thermal recording medium
CA2110524A1 (en) * 1992-12-10 1994-06-11 Gerald Burr Grindey Antitumor compositions and methods of treatment
JPH0747772A (en) * 1993-08-05 1995-02-21 New Oji Paper Co Ltd Thermal recording
WO1996036611A1 (en) 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
DE69625622T2 (en) * 1995-10-25 2003-08-14 Senju Pharmaceutical Co., Ltd. Angiogenesis inhibitors
US5929097A (en) 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
AU2879300A (en) * 1999-02-12 2000-08-29 Cellpath, Inc. Methods for anti-tumor therapy
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
AR031130A1 (en) 2000-09-20 2003-09-10 Abbott Lab PROMOTING N-ACILSULFONAMIDS OF APOPTOSIS
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters

Also Published As

Publication number Publication date
EA005810B1 (en) 2005-06-30
DE60213810T2 (en) 2007-02-01
BR0210078A (en) 2004-06-22
CA2446719A1 (en) 2002-12-12
DK1401806T3 (en) 2006-11-27
US20040157741A1 (en) 2004-08-12
CY1105386T1 (en) 2010-04-28
SK14642003A3 (en) 2004-12-01
PT1401806E (en) 2006-11-30
WO2002098848A1 (en) 2002-12-12
MY136855A (en) 2008-11-28
CR7182A (en) 2004-06-08
ZA200308644B (en) 2005-02-07
PE20030199A1 (en) 2003-03-12
EP1401806A1 (en) 2004-03-31
DE60213810D1 (en) 2006-09-21
AR036079A1 (en) 2004-08-11
CN1514824A (en) 2004-07-21
EG24356A (en) 2009-03-04
US7183320B2 (en) 2007-02-27
JP4167173B2 (en) 2008-10-15
EA200400006A1 (en) 2004-06-24
ECSP034874A (en) 2004-01-28
UA74889C2 (en) 2006-02-15
EP1401806B1 (en) 2006-08-09
HUP0400114A3 (en) 2007-05-02
NZ529098A (en) 2005-08-26
KR20040007656A (en) 2004-01-24
CZ20033296A3 (en) 2004-04-14
ES2269688T3 (en) 2007-04-01
HUP0400114A2 (en) 2005-04-28
PL367188A1 (en) 2005-02-21
ATE335722T1 (en) 2006-09-15
TWI266761B (en) 2006-11-21
HRP20031000A2 (en) 2004-04-30
CN100475787C (en) 2009-04-08
KR100880760B1 (en) 2009-02-02
IL158985A0 (en) 2004-05-12
NO20035366D0 (en) 2003-12-02
JP2004530709A (en) 2004-10-07
HK1064360A1 (en) 2005-01-28
NO20035366L (en) 2004-02-06
MXPA03011197A (en) 2004-02-26
AU2002259204B2 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
SV2003001076A (en) COMPOUNDS AND ANTITUMOR PROCEDURES REF. X-14776
SV2004001367A (en) ANTITUMOR COMPOUNDS AND PROCEDURES REF.X-15365
MXPA03008968A (en) Linear illumination source.
JO2410B1 (en) Substituted 6-pyrido-pyrimidines
SG143985A1 (en) Quinolinone derivatives
SG141459A1 (en) Novel quinoline derivatives
DK1414828T3 (en) Antitumor analogues
NO20042000D0 (en) Multi-user Content Procedure
DE60135919D1 (en) FARNESYL TRANSFERASE-INHIBITING 6-HETEROCYCLYLMETHYL-CHINOLINE AND CHINAZOLE DERIVATIVES
PT1473036E (en) SOLVATO OF HEMITARTARATO DE ZOLPIDEM
AU148078S (en) Bottle
AU2003290592A1 (en) Antitumor benzoylsulfonamides
SV2003000981A (en) PHENYL-HETEROCICLIL-ETERES REF. PCS10973
AU148415S (en) Bottle
MXPA04000541A (en) Lyophilized formulation comprising olanzapine.
GB2378068B (en) Bipolar differential amplifier
DE50207869D1 (en) METAL-ORGANIC ANTITUMSIDE
MXPA04004757A (en) Use of an ascomycin for the treatment of blepharitis.
GB0205327D0 (en) compounds
DE60220504D1 (en) Tryptasehemmer
DOP2002000329A (en) SOLID COMPOSITION
CY1115144T1 (en) UK-2A PRODUCERS
ES1049075Y (en) OFFICE TABLE
UA50920A (en) Support-centering unit
ES1050032Y (en) COORDINATED TABLE

Legal Events

Date Code Title Description
FD Lapse